Litigation Details for Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)
✉ Email this page to a colleague
Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)
Docket | ⤷ Try a Trial | Date Filed | 2022-08-08 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
Jury Demand | None | Referred To | |
Patents | 10,220,155; 10,335,462; 10,357,616; 10,376,652; 8,114,833; 8,129,343; 8,536,122; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; RE46,363 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc.
Biologic Drugs cited in Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. (D. Del. 2022)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2022-03-18 | 1 | 1/09/2018 Novo Nordisk A/S 13 10,220,155 3/05/2019 Novo…following n Trademarks or BfPatents. ( Q the patent action involves 35 U.S.C. § 292.): DOCKET…PHARMACEUTICALS INC. PATENT OR DATE OF PATENT … □ Other Pleading PATENT OR DATE OF PATENT …INC. NOVO NORDISK A/S PATENT OR DATE OF PATENT | External link to document | |
2022-12-21 | 61 | Notice of Service | U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462 filed… 8 August 2022 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
2023-03-22 | 85 | ANDA Form | U.S. Patent No. 9,687,611 expires on 2/27/2027; U.S. Patent Nos. 8,920,383, 9,775,953, 10,220,155, and…of Expiration of Patent: U.S. Patent No. 8,114,833 expires on 8/13/2025; U.S. Patent Nos. 8,684,969 and…expire on 1/20/2026; U.S. Patent No. 8,536,122 expires on 3/20/2026; Patent No. RE46,363 expires on 8/…expire on 7/17/2026; U.S. Patent No. 9,457,154 expires on 9/27/2027; U.S. Patent No. 9,132,239 expires on… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) | External link to document |
2023-03-22 | 86 | Patent/Trademark Report to Commissioner of Patents | 9,616,180; ;9,687,611; 9,775,953; 9,861,757; ;10,220,155; 10,335,462; 10,357,616; ;10,376,652; 11,097,… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,114,833; 8,129,343… 8 August 2022 1:22-cv-01040 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |